Previous studies addressing the function of milatuzumab are based on B-cell lines or B cells that are from patients with CLL and that express CD74 at high levels or mouse splenocytes and cell lines [1,4]. Here, CD74 is linked to B-cell chronic lymphocytic leukemia.